Theravance Biopharma (TBPH) Cash & Current Investments (2014 - 2026)

Theravance Biopharma (TBPH) has reported Cash & Current Investments for 13 consecutive years, with $394.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 201.61% year-over-year to $394.7 million; the TTM figure through Mar 2026 stood at $394.7 million (up 201.61% YoY), while the FY2025 annual figure was $315.4 million, up 256.94% from the prior year.
• Cash & Current Investments rose to $394.7 million in Q1 2026 per TBPH's latest filing, from $315.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $486.8 million in Q3 2022 and bottomed at $88.4 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $213.2 million across 5 years, with a median of $147.5 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 72.47% — and 2025, when it jumped 260.85%.
• Theravance Biopharma's Cash & Current Investments stood at $327.5 million in 2022, then slumped by 68.72% to $102.4 million in 2023, then fell by 13.74% to $88.4 million in 2024, then soared by 256.94% to $315.4 million in 2025, then climbed by 25.15% to $394.7 million in 2026.
• Business Quant data shows TBPH's Cash & Current Investments at $394.7 million in Q1 2026, $315.4 million in Q4 2025, and $329.7 million in Q3 2025.